Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure

American Heart Journal

Volumn 139, Issue 4, 2000, Pages

  Packer, Milton ^a  

^a Columbia Univ Coll of Phys and S ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; HEART FAILURE; HEMODYNAMICS; HUMAN; INTUITION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SAFETY;

EID: 0034126844     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90074-7     Document Type: Conference Paper

References (20)

1. 1. Packer M. Vasodilator and inotropic drugs for chronic heart failure: distinguishing hype from hope, J Am Coll Cardiol 1988;12:1299-317.
2. 2. Packer M. The placebo effect in heart failure. Am Heart J 1990; 120:1579-82.
3. 3. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993;71:3C-11C.
4. 4. Packer M, Meller J, Gorlin R, Herman MV. Clinical and hemodynamic tachyphylaxis to prazosin mediated afterload reduction in severe congestive heart failure. Circulation 1979;59:531-9.
5. 5. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
6. 6. Colucci WS, Alexander RW, Williams GH, et al. Decreased lymphocyte beta-adrenergic receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med 1981;305:185-90.
7. 7. Franciosa JA, Jordan RA, Wilen MM, Leddy CL. Minoxidil in patients with left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation 1984;70:63-9.
8. 8. Barjon JN, Rouleau J-L, Bichet D, Juneau C, De Champlain J. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987;9:622-30.
9. 9. Packer M, Carver JR, Rodeheffer RJ, et al, and the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
10. 10. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994;72:226-30.
11. 11. Hampton JR, van Veldhuisen DJ, Kleber FX, et al, on behalf of the PRIME II Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971-7.
12. 12. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-6.
13. 13. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
14. 14. Packer M, Miller AB. Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. Am J Cardiol 1999;84(suppl 1):1-2.
15. 15. Antonopoulos G, Lau J, Konstam MA, Udelson JE. Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure [abstract]? Circulation 1999;100 (suppl 1):1-296.
16. 16. Yee KM, Struthers AD. Can drug effects on mortality in heart failure be predicted by any surrogate measure? Eur Heart J 1997;18:1860-4.
17. 17. Lipicky R, Packer M. Role of surrogate endpoints in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993;22(suppl):179A-184A.
18. 18. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
19. 19. Packer M. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. J Am Coll Cardiol 1987;9:433-8.
20. 20. Feldman AM, Bristow MR, Parmley WW, et al, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.